# Torrent Pharmaceuticals (TORNTPHARM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/torntpharm

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹4,750
- Change: +0.85%
- As of: 2026-11-06
- 1D return: +0.85%
- 5D return: +2.96%
- 1M return: +2.88%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

TORNTPHARM closed at ₹4,750.0 on 2026-11-06, holding near the upper end of its 20-day range (+87.8%) but below key daily moving averages and the Supertrend. This creates a mixed technical picture: the monthly trend remains strongly bullish (ADX 59.54) with price above all major indicators, while the weekly structure is also bullish. However, the daily chart shows a bearish Supertrend direction and price below the 50-period SMA, suggesting short-term distribution or consolidation despite positive returns over the last 10 days (+5.0%).

Momentum is present but contested. Anomalies on 2026-10-23 and 2026-10-26 showed high participation with wide intraday ranges or lack of clear direction, indicating active trading without decisive follow-through. The stock is currently positioned between immediate support at ₹4,749.23 (0.02% below) and resistance at ₹4,788.47 (0.81% above). A break above ₹4,788.47 could signal a resumption of the daily uptrend toward ₹4,823.53. Conversely, a close below ₹4,749.23 would expose the next support level at ₹4,714.17 (-0.75%), potentially invalidating the short-term bullish bias.

Risk metrics show an annualized volatility of +21.9% and a current drawdown of -7.3%. While the long-term return since start is +38.9%, the recent 1-month return is slightly negative (-0.5%), highlighting near-term indecision.

- Trend Conflict: Monthly and weekly trends are bullish with strong ADX readings (59.54 and 33.24 respectively), but the daily Supertrend is bearish and price sits below the 50-period SMA, indicating short-term weakness against a longer-term uptrend.
- Key Levels: Immediate resistance is at ₹4,788.47 (+0.81%) and ₹4,823.53 (+1.55%). Critical support lies at ₹4,749.23 (near current price) and ₹4,714.17 (-0.75%).
- Momentum & Participation: Recent anomalies on 2026-10-23 and 2026-10-26 showed high volume participation (volume ratio 2.08) but no clear directional follow-through, suggesting active but undecided trading.
- Risk Profile: Annualized volatility is +21.9% with a current drawdown of -7.3%. The stock is in the upper-middle of its 252-day range (+70.9%), leaving limited upside before higher historical resistances.

- Bullish Engulfing Reversal
- Inside Bar
- Outside Bar
- Harami

### News Context

In the seven-day window ending November 5, 2026, Torrent Pharmaceuticals received renewed attention from domestic brokerages. On November 3, SMIFS included the company among its top stock picks for November, citing a broader resurgence in buying interest for Indian equities driven by supportive domestic and global cues, including eased crude oil prices and strong economic growth. The firm provided detailed technical analysis with specific buy ratings, target prices, and stop-loss levels for Torrent Pharma alongside other selected counters. Subsequently, on November 5, Geojit Financial Services issued a 'Buy' recommendation for the pharmaceutical company, setting a specific target price of ₹5,581. These developments reflect external analyst optimism regarding the stock's valuation and near-term potential, though they represent third-party opinions rather than verified corporate operational changes.

- SMIFS named Torrent Pharma a top pick for November (reported Nov 3), attributing positive outlook to eased crude prices and strong economic growth, while providing specific technical targets and stop-loss levels.
- Geojit Financial Services issued a 'Buy' rating with a target price of ₹5,581 (reported Nov 5), suggesting potential upside based on current valuation metrics.
- Both recommendations highlight external confidence in the stock, but these are analyst opinions and do not constitute factual corporate announcements or guaranteed investment outcomes.

- [Buy Torrent Pharmaceuticals; target of Rs 5581: Geojit Financial Services](https://www.moneycontrol.com/news/business/stocks/buy-torrent-pharmaceuticals-target-of-rs-5581-geojit-financial-services-14071350.html)
- [HPCL, DLF, Torrent Pharma among top picks for November; check price targets, risk-reward & more](https://www.businesstoday.in/markets/trending-stocks/story/hpcl-dlf-torrent-pharma-among-top-picks-for-november-check-price-targets-risk-reward-more-565289-2026-11-03)

### Official Filings

Torrent Pharmaceuticals reported consolidated revenue of ₹4,979 crores for Q2 FY27, marking a 51% year-on-year increase from ₹3,302 crores, driven by the amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma). The merger, effective July 8, 2026, with an appointed date of January 21, 2026, resulted in the allotment of 4,19,22,416 equity shares. Consolidated profit after tax stood at ₹534 crores for the quarter and ₹1,100 crores for H1 FY27.

In regulatory developments, the company received orders on November 4, 2026, imposing a GST penalty of ₹3,12,32,860 related to JB Pharma’s operations for FY 2020-21 to FY 2023-24. Torrent Pharmaceuticals stated it will file an appeal and does not reasonably expect a material financial impact. Additionally, the Registrar to an Issue, KFin Technologies, is shifting its corporate office address effective December 1, 2026.

- Q2 FY27 consolidated revenue rose 51% YoY to ₹4,979 crores, reflecting the inclusion of JB Pharma following the July 2026 amalgamation.
- Consolidated PAT was ₹534 crores for Q2 and ₹1,100 crores for H1 FY27; 4,19,22,416 new shares were allotted upon merger completion.
- GST penalty of ₹3,12,32,860 imposed for pre-acquisition periods (FY 2020-24); company intends to appeal and expects no material impact.

- [Torrent Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/TORNTPHARM_05112026174131_SE_Intimation05112026.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication - Newspaper advertisement in respect of special window for transfer and dematerialization requests of physical shares |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/TORNTPHARM_04112026181058_SEIntimationAdvtSpeical_window_for_physical_transfer04112026.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/TORNTPHARM_04112026185329_SE_IntimationchangeinRTAaddress.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/TORNTPHARM_29102026095442_SE_IntimationTranscriptofConfCall.pdf)
- [Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/TORNTPHARM_23102026164512_Results.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 23, 2026, titled "A Press Release on Financial Results which is being submitted to the media is also enclosedherewith as an Annexure B.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/TORNTPHARM_23102026165000_outcome.pdf)
- [Security Cover |SUBJECT: Security Cover](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026165215_security_cover.pdf)
- [Security Cover |SUBJECT: Security Cover](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026165536_seccover.pdf)
- [Statement of utilization of issue proceeds |SUBJECT: Statement of utilization of issue proceeds](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026170007_52.pdf)
- [Statement of deviation/variation in use of Issue proceeds |SUBJECT: Statement of deviation/variation in use of Issue proceeds](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026170015_52.pdf)

### Fundamentals

Torrent Pharmaceuticals is executing a significant expansion phase, marked by a surge in sales to ₹17,400 crore (TTM) and a 51% YoY growth in the September 2026 quarter. However, earnings quality faces pressure as net profit growth stagnates (0% TTM) despite rising revenues, driven by a sharp increase in finance costs to ₹886 crore (TTM) and higher depreciation of ₹609 crore in Q2 FY2026-27. The balance sheet has expanded materially, with total assets jumping from ₹15,515 crore to ₹44,615 crore year-over-year, supported by increased borrowings (₹14,107 crore as of Sep 2026) and equity infusion. While operating cash flow remains robust at ₹3,023 crore for Mar 2026, the cash conversion cycle has lengthened to 163 days, and ROCE declined to 15% in Mar 2026 from 27% the prior year. Promoter holding diluted to 60.78%, while FIIs and DIIs increased their stakes, reflecting institutional confidence in the growth trajectory despite margin compression.

- Revenue momentum is strong with 51% YoY sales growth in Sep 2026, but net profit growth is flat at 0% (TTM), indicating margin pressure from rising interest and depreciation costs.
- Balance sheet leverage has increased significantly; borrowings rose to ₹14,107 crore (Sep 2026) and total assets nearly tripled to ₹44,615 crore, funding a major capacity expansion.
- Return on Capital Employed (ROCE) dropped to 15% in Mar 2026 from 27% in Mar 2025, and the cash conversion cycle extended to 163 days, signaling working capital efficiency challenges during expansion.
- Institutional ownership is rising: FIIs hold 17.22% and DIIs 13.37% (Sep 2026), while promoter stake decreased to 60.78%, suggesting external capital is backing the growth strategy.

### Bear Case

Torrent Pharmaceuticals faces near-term technical headwinds despite a strong yearly performance. On the daily chart, the stock is in a bearish trend with the Supertrend indicating downward pressure and both the 20-day and 50-day simple moving averages showing negative slopes (-10.06 and -25.79 respectively). The price has pulled back from recent highs, resulting in a current drawdown of -7.3% against a maximum historical drawdown of -14.9%. While the monthly trend remains bullish (Supertrend: bullish) and the stock is up +33.7% over the past year, the short-term momentum is weakening, evidenced by a -4.2% return over the last three months and a slight decline of -0.5% over the past month. Immediate support is thin, with the nearest pivot level at ₹4,714.17 just 0.75% below the closing price of ₹4,750.00. Investors should monitor whether the price holds above this pivot; a break below could expose further downside toward ₹4,674.93.

- Daily trend is bearish with negative slopes on 20-day and 50-day SMAs, contrasting with a bullish monthly outlook.
- Current drawdown stands at -7.3%, approaching the historical maximum drawdown of -14.9%.
- Short-term momentum has softened, with returns of -4.2% over 3 months and -0.5% over 1 month.
- Critical support lies at ₹4,714.17 (0.75% below close); failure to hold may trigger further technical weakness.

- [Buy Torrent Pharmaceuticals; target of Rs 5581: Geojit Financial Services](https://www.moneycontrol.com/news/business/stocks/buy-torrent-pharmaceuticals-target-of-rs-5581-geojit-financial-services-14071350.html)
- [HPCL, DLF, Torrent Pharma among top picks for November; check price targets, risk-reward & more](https://www.businesstoday.in/markets/trending-stocks/story/hpcl-dlf-torrent-pharma-among-top-picks-for-november-check-price-targets-risk-reward-more-565289-2026-11-03)
- [Torrent Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/TORNTPHARM_05112026174131_SE_Intimation05112026.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication - Newspaper advertisement in respect of special window for transfer and dematerialization requests of physical shares |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/TORNTPHARM_04112026181058_SEIntimationAdvtSpeical_window_for_physical_transfer04112026.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/TORNTPHARM_04112026185329_SE_IntimationchangeinRTAaddress.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/TORNTPHARM_29102026095442_SE_IntimationTranscriptofConfCall.pdf)
- [Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/TORNTPHARM_23102026164512_Results.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 23, 2026, titled "A Press Release on Financial Results which is being submitted to the media is also enclosedherewith as an Annexure B.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/TORNTPHARM_23102026165000_outcome.pdf)
- [Security Cover |SUBJECT: Security Cover](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026165215_security_cover.pdf)
- [Security Cover |SUBJECT: Security Cover](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026165536_seccover.pdf)

### FAQs

**What is the material financial impact of the recent GST penalty order on Torrent Pharmaceuticals?**

The Commercial Tax Officer in Tamil Nadu imposed a penalty of ₹3,12,32,860 for FY 2020-21 to FY 2023-24. This demand relates to JB Chemicals and Pharmaceuticals Limited prior to its acquisition by Torrent. The company received the order on November 4, 2026, intends to file an appeal, and stated it does not reasonably expect a material financial impact.

**How has Torrent Pharmaceuticals performed over the past year compared to its current short-term trend?**

Over the trailing one-year period, the stock delivered a return of +33.7%, with a year-to-date return of +23.4%. However, the daily technical trend is currently bearish, with the price closing at ₹4,750.00 on November 6, 2026, after a one-month return of -0.5% and a three-month return of -4.2%.

**What are the key support and resistance levels for Torrent Pharmaceuticals as of November 6, 2026?**

Immediate support is observed at ₹4749.23 (0.02% below), followed by ₹4714.17 (pivot) and ₹4674.93 (low). Resistance levels are located at ₹4788.47 (0.81% above), ₹4823.53 (1.55% above), and ₹5021.17 (5.71% above). The stock traded between a low of ₹4699.1 and a high of ₹4789.5 on this date.

- [Buy Torrent Pharmaceuticals; target of Rs 5581: Geojit Financial Services](https://www.moneycontrol.com/news/business/stocks/buy-torrent-pharmaceuticals-target-of-rs-5581-geojit-financial-services-14071350.html)
- [HPCL, DLF, Torrent Pharma among top picks for November; check price targets, risk-reward & more](https://www.businesstoday.in/markets/trending-stocks/story/hpcl-dlf-torrent-pharma-among-top-picks-for-november-check-price-targets-risk-reward-more-565289-2026-11-03)
- [Torrent Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/TORNTPHARM_05112026174131_SE_Intimation05112026.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication - Newspaper advertisement in respect of special window for transfer and dematerialization requests of physical shares |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/TORNTPHARM_04112026181058_SEIntimationAdvtSpeical_window_for_physical_transfer04112026.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/TORNTPHARM_04112026185329_SE_IntimationchangeinRTAaddress.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/TORNTPHARM_29102026095442_SE_IntimationTranscriptofConfCall.pdf)
- [Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/TORNTPHARM_23102026164512_Results.pdf)
- [Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 23, 2026, titled "A Press Release on Financial Results which is being submitted to the media is also enclosedherewith as an Annexure B.". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/TORNTPHARM_23102026165000_outcome.pdf)
- [Security Cover |SUBJECT: Security Cover](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026165215_security_cover.pdf)
- [Security Cover |SUBJECT: Security Cover](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026165536_seccover.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹4,714.17
- Risk regime: Price Risk Currently Contained

### Support levels
- 4259.2
- 4237.44375
- 4065.1

### Resistance levels
- 5021.165625
- 5250
- 4788.466666666666

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.85% |
| return_10 | +4.99% |
| return_1m | -0.46% |
| return_1y | +33.67% |
| return_20 | +2.88% |
| return_3m | -4.16% |
| return_5 | +2.96% |
| return_6m | +8.99% |
| return_since_start | +38.95% |
| return_ytd | +23.43% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -14.86% |
| annualized_volatility | +21.87% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Torrent Pharmaceuticals Limited FY2026-27 Q2: Revenue edges up, profit falls

Consolidated revenue from operations rose 1.2% quarter on quarter to ₹4,979 crore, up 50.8% year on year. Profit for the period declined 5.7% sequentially to ₹534 crore and 9.6% from Q2 FY26; a higher tax expense more than offset the sequential benefit from a smaller exceptional charge.

## Revenue and expenses

Revenue increased from ₹4,197 crore in Q4 FY26 to ₹4,921 crore in Q1 FY27 and ₹4,979 crore in Q2 FY27. It was ₹3,303 crore in Q3 FY26 and ₹3,302 crore in Q2 FY26.

Expenses rose 1.6% quarter on quarter to ₹4,222 crore, faster than revenue. Other expenses eased to ₹1,194 crore from ₹1,201 crore in Q1 FY27. Q2 FY27 employee benefit expense was ₹895 crore and depreciation and amortisation expense was ₹609 crore.

## Profit, tax and earnings per share

Profit before exceptional items and tax was ₹747 crore, down from ₹754 crore in Q1 FY27 and ₹804 crore in Q2 FY26. The exceptional charge narrowed to ₹10 crore from ₹21 crore in Q1 FY27, taking profit before tax to ₹737 crore, compared with ₹733 crore in Q1 FY27 and ₹791 crore in Q2 FY26.

Tax expense increased to ₹203 crore from ₹167 crore in Q1 FY27. Profit for the period consequently fell to ₹534 crore from ₹566 crore in the prior quarter and ₹591 crore a year earlier. Basic and diluted EPS were both ₹14.05, versus ₹14.87 in Q1 FY27 and ₹17.45 in Q2 FY26.

## Balance sheet and liquidity

At 30 September 2026, cash and cash equivalents were ₹891 crore, compared with ₹1,117 crore at 31 March 2026. Current investments rose to ₹2,073 crore from ₹866 crore over the same dates.

Inventories were ₹3,182 crore and trade receivables ₹3,398 crore at 30 September 2026, up from ₹3,138 crore and ₹3,031 crore, respectively, at 31 March 2026. These increases warrant monitoring alongside the quarter’s revenue growth.

Total assets were ₹44,615 crore at 30 September 2026, with liabilities of ₹26,242 crore and equity of ₹18,373 crore. Property, plant and equipment stood at ₹5,066 crore, other intangible assets at ₹23,352 crore and goodwill at ₹3,990 crore. Noncurrent borrowings were ₹11,620 crore and current borrowings ₹2,254 crore, compared with ₹11,651 crore and ₹3,147 crore, respectively, at 31 March 2026.

## Key Takeaway

Revenue continued to grow sequentially, but expenses rose faster and profit and EPS declined from both Q1 FY27 and Q2 FY26. The narrower exceptional charge lifted profit before tax slightly quarter on quarter, but higher tax expense contributed to the lower reported profit; the increases in receivables and inventories are also worth tracking.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +60.78%
- FII holding: +17.97%
- DII holding: +12.77%
- Mutual fund holding: +8.27%
- Retail holding: +4.43%
- Promoter pledged: +0.00%

### Major reported shareholders

- TORRENT INVESTMENTS LIMITED (FORMERLY KNOWN AS TORRENT INVESTMENTS PRIVATE LIMITED) — +60.78% (Bodies Corporate)
- NPS TRUST — +2.23%
- AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUND A/C — +1.28%
- KOTAK CONTRA FUND — +1.18%
- HDFC MUTUAL FUND - HDFC INNOVATION FUND — +1.03%

## Official filings

- 2026-11-06 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_06112026183143_SE_Intimation_Analyst_Meet0611.pdf)
- 2026-11-06 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_305_WebXMLFile_20261106_184349793.xml)
- 2026-11-06 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_305_WebXMLFile_20261106_184312842.xml)
- 2026-11-05 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_05112026174131_SE_Intimation05112026.pdf)
- 2026-11-04 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_04112026181058_SEIntimationAdvtSpeical_window_for_physical_transfer04112026.pdf)
- 2026-11-04 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_04112026185329_SE_IntimationchangeinRTAaddress.pdf)
- 2026-10-29 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_29102026095442_SE_IntimationTranscriptofConfCall.pdf)
- 2026-10-23 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_23102026164512_Results.pdf)
- 2026-10-23 — Press Release: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_23102026165000_outcome.pdf)
- 2026-10-23 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026165215_security_cover.pdf)
- 2026-10-23 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026165536_seccover.pdf)
- 2026-10-23 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026170007_52.pdf)
- 2026-10-23 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/content/debt/WDM/TORNTPHARM_23102026170015_52.pdf)
- 2026-10-23 — Financial Results Filing: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1744988_23102026072530_WEB.xml)
- 2026-10-23 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_23102026193638_Audio_recording.pdf)
- 2026-10-23 — Financial Results Filing: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745013_23102026080745_WEB.xml)
- 2026-10-23 — Financial Results Filing: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745043_23102026081504_WEB.xml)
- 2026-10-23 — Financial Results Filing: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745044_23102026081509_WEB.xml)
- 2026-10-16 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_16102026180229_SE_IntimationSMP.pdf)
- 2026-10-16 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_305_WebXMLFile_20261016_183920322.xml)
- 2026-10-16 — Management Change: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_ROID_100692_KMP_Doc.zip)
- 2026-10-09 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_09102026114110_SEIntimationConcallQ2.pdf)
- 2026-10-09 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_305_WebXMLFile_20261009_172036194.xml)
- 2026-10-09 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_305_WebXMLFile_20261009_172006290.xml)
- 2026-10-07 — Credit Rating Update: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_07102026193222_SEIntimationIndiaRatings071026.pdf)

## News and market events

- 2026-11-05 — MONEYCONTROL: **Buy Torrent Pharmaceuticals; target of Rs 5581: Geojit Financial Services** — Geojit Financial Services has issued a 'Buy' recommendation for Torrent Pharmaceuticals, setting a target price of Rs 5,581. The brokerage's note suggests potential upside for investors in the pharmaceutical company based on this specific valuation. — [Source](https://www.moneycontrol.com/news/business/stocks/buy-torrent-pharmaceuticals-target-of-rs-5581-geojit-financial-services-14071350.html)
- 2026-11-03 — BUSINESSTODAY: **HPCL, DLF, Torrent Pharma among top picks for November; check price targets, risk-reward & more** — Domestic brokerage firm SMIFS has identified Hindustan Petroleum Corporation Ltd, DLF Ltd, and Torrent Pharmaceuticals as top stock picks for November, citing renewed buying interest in Indian equities driven by supportive domestic and global cues. The firm attributes the positive outlook for these specific counters to factors such as eased crude oil prices and strong economic growth, while providing detailed technical analysis including buy ratings, target prices, and stop-loss levels for each. — [Source](https://www.businesstoday.in/markets/trending-stocks/story/hpcl-dlf-torrent-pharma-among-top-picks-for-november-check-price-targets-risk-reward-more-565289-2026-11-03)
- 2026-10-25 — The Hindu: **Torrent Pharma eyes semaglutide launch in Brazil in 6-9 months** — Torrent Pharmaceuticals plans to launch semaglutide in Brazil over the next six to nine months, as the drugmaker seeks to expand its presence in a market where revenues grew 38 per cent in the September quarter, Managing Director Aman Mehta said. — [Source](https://www.thehindubusinessline.com/companies/torrent-pharma-eyes-semaglutide-launch-in-brazil-in-6-9-months/article71623182.ece)
- 2026-10-23 — FREEPRESSJOURNAL.IN: **Torrent Pharma Profit Falls 9.6 Per Cent, Dr Reddy’s Slumps 36 Pc In Q2 FY27** — Torrent Pharmaceuticals’ Q2 FY27 net profit fell 9.6% to Rs 534 crore, although revenue rose 50.8% to Rs 4,979 crore as expenses climbed 70.9%. Dr Reddy’s Laboratories reported a 36% profit decline to Rs 913.4 crore; revenue slipped 1.5% to Rs 8,671 crore and EBITDA fell 24.2% to Rs 1,783 crore, with its margin narrowing to 20.6%. — [Source](https://www.freepressjournal.in/business/torrent-pharma-profit-falls-96-per-cent-dr-reddys-slumps-36-pc-in-q2-fy27)
- 2026-10-23 — FREEPRESSJOURNAL.IN: **Torrent Pharmaceuticals Q2 Results FY27: Net Profit Falls 9.64% To ₹534 Crore Despite 50.78% Revenue Growth** — Torrent Pharmaceuticals reported a 9.64 per cent decline in consolidated net profit to ₹534 crore for Q2 FY27, despite revenue surging 50.78 per cent to ₹4,979 crore. Expenses increased to ₹4,222 crore. India, US and Brazil revenues grew 20, 24 and 38 per cent, respectively, while Germany declined 7 per cent. Half-yearly net profit fell 3.42 per cent. — [Source](https://www.freepressjournal.in/business/torrent-pharmaceuticals-q2-results-fy27-net-profit-falls-964-to-534-crore-despite-5078-revenue-growth)
- 2026-10-23 — CNBC-TV18: **Torrent Pharma Q2 Results: Net profit declines despite 51% revenue growth; misses estimates** — Torrent Pharmaceuticals reported a 9.6% YoY decline in Q2 FY27 net profit to ₹534 crore, while revenue grew 50.8% to ₹4,979 crore. EBITDA rose 54.1% to ₹1,583 crore, with the margin improving to 32.33%, although both EBITDA and net profit missed poll estimates. — [Source](https://www.cnbctv18.com/market/stocks/torrent-pharma-share-price-q2-results-net-profit-declines-despite-51-revenue-growth-misses-estimates-20018208.htm)
- 2026-10-23 — The Hindu: **Torrent Pharma Q2 net profit falls 10% to ₹534 crore; revenue rises 51%** — In the first half of FY27, Torrent Pharma’s revenue rose 52.8 per cent to ₹9,900 crore, while net profit fell 3.4 per cent to ₹1,100 crore. — [Source](https://www.thehindubusinessline.com/companies/torrent-pharma-q2-net-profit-falls-10-to-534-crore-revenue-rises-51/article71615894.ece)
- 2026-10-23 — The Hindu: **Q2 Results Today Live: Infosys, Adani Power, JSW Steel, Tata Motors, Shriram Fin, Torrent Pharma, CG Power, BPCL, Dr Reddys Lab Share to announce Q2 results** — Q2 Results Today, 23rd October 2026 Live Updates: Follow the latest announcements and developments on the company's September quarter earning on Adani Power, JSW Steel, Tata Motors, Shriram Fin, Torrent Pharma, CG Power, BPCL, Dr Reddys Laband others — [Source](https://www.thehindubusinessline.com/companies/q2-results-today-live-updates-infosys-adani-power-jsw-steel-tata-motors-shiram-fin-torrent-pharma-cg-power-bpcl-dr-reddys-lab-company-results-23-october-2026/article71611542.ece)
- 2026-10-19 — Economic Times: **Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players** — India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceutical Industries and Aurobindo Pharma are likely to report good growth. In contrast, Dr Reddy's Laboratories and Lupin may face challenges due to increased competition and a high base. Pricing pressure and elevated raw material costs are also expected to impact overall performance. — [Source](https://economictimes.indiatimes.com/markets/stocks/earnings/indias-pharmaceutical-companies-to-report-mixed-results-as-domestic-growth-offsets-pricing-pressures/articleshow/135037267.cms)
- 2026-10-18 — Mint: **Who is Amal Kelshikar? Why did he resign from the position of Torrent Pharmaceuticals' Executive Director? Explained | Company Business News** — Torrent Pharmaceuticals accepted Executive Director Amal Kelshikar’s resignation, effective at the close of business on 16 October 2026. Kelshikar said in his resignation letter that he was stepping down after reflection and believed it was the right time to transition. — [Source](https://www.livemint.com/companies/people/who-is-amal-kelshikar-why-did-he-resign-from-the-position-of-torrent-pharmaceuticals-executive-director-explained-11792346219762.html)
- 2026-09-28 — The Hindu: **Torrent Pharma raises investment in Torrent Urja 27 to ₹11.88 cr to acquire 26% stake** — Torrent Pharma raises its investment in Torrent Urja 27 to ₹11.88 cr for a 26% stake in a Gujarat captive solar-wind project. — [Source](https://www.thehindubusinessline.com/markets/torrent-pharma-raises-investment-in-torrent-urja-27-to-1188-cr-to-acquire-26-stake/article71519469.ece)
- 2026-09-22 — REDIFF.COM: **Top Pharma Firms Maintain Volume Growth Amid Market Shift to Chronic Therapies** — India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies. — [Source](https://www.rediff.com/business/report/indias-top-10-pharma-companies-sustain-volume-growth-outperforming-smaller-rivals/20260922.htm)
- 2026-09-17 — Mint: **Bandhan Small Cap Fund August portfolio: Cyient, P N Gadgil see higher holdings; 4 stocks added, 6 exited | Mint** — Bandhan Small Cap Fund attracted ₹2,187 crore in August, the highest inflow among small-cap schemes, as it reshuffled several existing holdings and added four new stocks. Cyient, P N Gadgil Jewellers and Strides Pharma were among the stocks where holdings increased. — [Source](https://www.livemint.com/money/personal-finance/bandhan-small-cap-fund-august-portfolio-cyient-p-n-gadgil-see-higher-holdings-4-stocks-added-6-exited-11789636919234.html)
- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-09-08 — Economic Times: **Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake** — Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector. — [Source](https://economictimes.indiatimes.com/news/company/corporate-trends/tata-capital-healthcare-fund-to-exit-linux-laboratories-as-chryscapital-buys-20-25-stake/articleshow/133939441.cms)
- 2026-08-20 — CNBC-TV18: **Ruby Mills sells 33rd-floor commercial space at The Ruby to Torrent Pharma for ₹124 crore** — Shares of The Ruby Mills Ltd ended at ₹412.80, up by ₹1.15, or 0.28%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/ruby-mills-share-price-sells-33rd-floor-commercial-space-at-the-ruby-to-torrent-pharma-for-rs-124-crore-19973774.htm)
- 2026-07-31 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty hits 24,400 mark; market at day's high** — Sensex Today | Stock Market Live Updates: We are the last half the week's trade, and the Indian markets are trading on a cautious note. The Nifty is looking to close the week in green, and is trading around 24,300. The Nifty Bank is trying to hold it together, now up around 100 points, moving around 57,250. TCS, Infosys and Wipro are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-it-infosys-banks-tata-steel-swiggy-sun-pharma-mdl-bajaj-fin-share-price-liveblog-19958369.htm)
- 2026-07-31 — The Hindu: **Q1 Results Today Live: Maruti Suzuki, Sun Pharma, Bajaj Finserv, ITC, IOC, Dixon, Bajaj Holdings, ABB India, Kirloskar Brothers, BlueDart, Glenmark, Aether to announce Q1 results, Bajaj Finance, M&M, Hyundai shares up, Vedanta & Tata Steel flat, Swiggy declines, Thermax drags after Q1** — Q1 Results Today, 31st July 2026 Live Updates: Stay tuned for more from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-maruti-suzuki-sun-pharma-dixon-tech-bajaj-holdings-abb-india-kirloskar-brothers-bluedart-glenmark-pharma-bajaj-finserv-itc-ioc-aether-ind-results-31-july-2026/article71285346.ece)
- 2026-07-31 — MONEYCONTROL: **Buzzing Stocks | RailTel slips 3% on mixed Q1 earnings; Astra Microwave gains 12% on ₹2,205 crore HAL order** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/stocks/buzzing-stocks-railtel-corporation-falls-3-on-mixed-earnings-astra-microwave-surges-2-on-hal-order-of-2-205cr-13989653.html)
- 2026-07-31 — BUSINESSTODAY: **Top stocks in news: Tata Steel, Bajaj Finance, Swiggy, Mazagon, RailTel, LIC Housing, Medanta** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Bajaj Finance, Swiggy, Tata Steel, Mazagon Dock Shipbuilders, Torrent Pharmaceuticals, LIC Housing Finance, AWL Agri Business, RailTel Corporation of India, Aarti Industries, Indegene, Global Health, Chambal Fertilisers & Chemicals, Thermax, Data Patterns (India), Rainbow Children's Medicare, Satin Creditcare Network, GNG Electronics, MOIL, Nucleus Software Exports — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-tata-steel-bajaj-finance-swiggy-mazagon-railtel-lic-housing-medanta-546413-2026-07-31)
- 2026-07-30 — Mint: **Domestic focus powers Torrent, Mankind in June quarter | Company Business News** — India-focused drugmakers outpaced US-facing peers as strong domestic demand and acquisitions drove double-digit June-quarter growth. — [Source](https://www.livemint.com/companies/company-results/domestic-focus-powers-torrent-mankind-in-june-quarter-medicine-pharma-merger-growth-acquisition-11785423266899.html)
- 2026-07-30 — CNBC-TV18: **Q1 Results LIVE Updates: RailTel profit flat, JBM Auto margin expands** — Q1 Results LIVE Updates: Bajaj Finance, M&M and Tata Steel are the three Nifty results for the day, along with broader market names like Hyundai Motor, Vedanta, Vedanta Aluminium, Swiggy, Mazagon Dock, Torrent Pharma, Thermax and many others. Eicher Motors, Dabur, three Vedanta demerged units, Bajaj Housing, Hexaware and many more also react to numbers. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-bajaj-finance-mm-tata-steel-eicher-dabur-mazagon-dock-swiggy-syngene-irfc-vedanta-aluminium-mtar-hyundai-lic-liveblog-19957385.htm)
- 2026-07-22 — Times of India: **Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla slide over 3%** — India Business News: Pharmaceutical stocks came under pressure on Wednesday after US President Donald Trump unveiled a phased tariff plan for imported generic medicines, r. — [Source](https://timesofindia.indiatimes.com/business/india-business/pharma-stocks-bleed-after-trump-announces-upto-200-tariff-on-generic-drugs/articleshow/132551541.cms)
- 2026-07-22 — Economic Times: **Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028** — Indian pharma stocks are likely to remain in focus after US President Donald Trump announced a phased tariff plan for generic medicines, offering a two-year tariff exemption before imposing steep duties from 2028. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/sun-pharma-cipla-other-pharma-stocks-in-focus-as-trump-unveils-100-200-tariffs-on-generic-drugs-from-2028/articleshow/132550249.cms)
- 2026-07-22 — News18: **Dr Reddy, Aurobindo, Cipla: Pharma Stocks To Remain In Focus Today After Trump's New Generic Drugs Tariff Plan** — Imported generic medicines will remain tariff-free for two years from August 1, after which the US plans to impose a 100% duty for one year and a 200% tariff thereafter. — [Source](https://www.news18.com/business/markets/dr-reddy-aurobindo-cipla-pharma-stocks-to-remain-in-focus-today-after-trumps-new-generic-drugs-tariff-plan-ws-l-10226357.html)

## Business profile

**Strategic vision:** Develops, manufactures, and markets pharmaceutical products globally.

### Business segments
- **Cardiovascular:** Focuses on the development and sale of pharmaceutical products within the cardiovascular therapeutic area.
- **Central Nervous System:** Focuses on the development and sale of pharmaceutical products within the central nervous system therapeutic area.
- **Gastro-intestinal:** Focuses on the development and sale of pharmaceutical products within the gastro-intestinal therapeutic area.
- **Diabetology:** Focuses on the development and sale of pharmaceutical products within the diabetology therapeutic area.
- **Anti-infective:** Focuses on the development and sale of pharmaceutical products within the anti-infective therapeutic area.
- **Pain Management:** Focuses on the development and sale of pharmaceutical products within the pain management therapeutic area.
- **Nephrology:** Has a presence in the nephrology segment.
- **Oncology:** Has a presence in the oncology segment.
- **Gynecology:** Has a presence in the gynecology segment.
- **Respiratory:** Has a presence in the respiratory segment.
- **Pediatrics:** Has a presence in the pediatrics segment.
- **Vaccines and Diagnostics:** Involves the development and selling of specialized products like vaccines and diagnostics.
- **Other Products:** Includes pharmaceuticals, generic drugs, over-the-counter drugs, contact lenses, and animal health products.

### Competitive strengths
- Global presence in over 40 countries
- More than 2,000 product registrations globally
- Operations across multiple key therapeutic areas

## Related stocks

- [Aurobindo Pharma Limited (Healthcare)](https://faxioms.com/stocks/auropharma) — +0.84%
- [Cipla Limited (Healthcare)](https://faxioms.com/stocks/cipla) — +0.49%
- [Divi's Laboratories Limited (Healthcare)](https://faxioms.com/stocks/divislab) — +1.78%
- [Dr. Reddy's Laboratories Limited (Healthcare)](https://faxioms.com/stocks/drreddy) — +0.51%
- [Laurus Labs Limited (Healthcare)](https://faxioms.com/stocks/lauruslabs) — -0.26%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/torntpharm
Markdown representation: https://faxioms.com/stocks/torntpharm?render=md